Georgia Advanced Maternal Age IVF Success Rates: Clinical Data and Influencing Factors for Women Over 40

Clinic Record: Success Rate Assessment for a 43-Year-Old Patient

A 43-year-old female patient presented to the clinic with recent AMH test results (0.6 ng/mL) and a vaginal ultrasound report (antral follicle count of 3). She had previously retrieved 2 and 1 oocytes in two cycles, respectively, neither of which resulted in a transferable blastocyst. She plans to travel to Georgia for her next treatment cycle. Her core question is: given her current ovarian reserve status, what is her probability of achieving a successful pregnancy in Georgia, and are there any overlooked viable pathways?

Georgia Advanced Maternal Age IVF Success Rates: Clinical Data Stratified by Age

The success rate data from Georgian assisted reproductive institutions are generally in the same range as those of major European countries (Spain, Czech Republic, Greece). According to summary data released at the 40th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) and annual reports from local Georgian fertility centers, the following are reference ranges for live birth rates per single embryo transfer using autologous oocytes:

The above data reflect the true prognosis when using autologous oocytes. Some Georgian fertility centers report slightly higher live birth rates for the ≥45 age group compared to the European average, but these data typically come from highly selected cases (e.g., AMH ≥1.0 ng/mL, no comorbidities) and are not routine outcomes; they should not be interpreted as a general expectation.

Who is Suitable for Advanced Maternal Age IVF in Georgia

Suitable candidates include: ① Women aged 40–44 with AMH ≥0.5 ng/mL, antral follicle count ≥3, and no severe uterine pathology; ② Those who need to utilize PGT-A (embryo chromosomal screening) or egg donation options permitted by Georgian law; ③ Those with a limited budget who still wish to access technical support comparable to major European centers.

Who is Not Suitable

Unsuitable situations include: ① Age ≥45 with AMH <0.3 ng/mL, where the live birth rate with autologous oocytes is extremely low, and egg donation should be prioritized; ② Presence of uncontrolled thyroid disease, autoimmune disease, or intrauterine adhesions, which require treatment in the home country first; ③ Unrealistic expectations of success (e.g., believing the live birth rate per single cycle exceeds 40%).

Why Advanced Maternal Age IVF Success Rates Decline Significantly: A Reproductive Medicine Perspective

From a reproductive biology standpoint, women are born with a fixed number of oocytes. With advancing age, not only does the ovarian follicle pool continuously deplete, but more importantly, oocyte quality declines non-linearly. Mitochondrial dysfunction, abnormal spindle assembly, and increased rates of chromosomal segregation errors collectively cause the embryo aneuploidy rate to rise sharply after age 40. Even blastocysts with good morphological grading have a far lower probability of being chromosomally normal compared to those from younger women. This is a biological limitation that current assisted reproductive technologies cannot reverse and is the core reason why IVF success rates for advanced maternal age are lower than for younger patients.

How Clinicians Assess Success Rates for Older Patients: Interpretation of Key Diagnostic Indicators

In reproductive medicine clinical decision-making, the following indicators are used to predict ovarian response to stimulation and the probability of embryo euploidy in older patients:

• AMH (Anti-Müllerian Hormone): A quantitative marker of ovarian reserve. AMH ≥1.0 ng/mL suggests an expected oocyte yield of ≥6 and a relatively higher cumulative live birth rate; AMH <0.5 ng/mL indicates poor ovarian response, with a single-cycle oocyte yield typically ≤3.
• FSH (Follicle-Stimulating Hormone) and LH (Luteinizing Hormone): Basal FSH >10 IU/L indicates diminished ovarian reserve, and >15 IU/L usually predicts a limited oocyte yield. An FSH/LH ratio >2.5 also suggests reduced ovarian responsiveness.
• Antral Follicle Count (AFC): A total antral follicle count in both ovaries <5 is directly associated with a high cycle cancellation rate and low oocyte yield.
• Thyroid Function and Vitamin D Levels: TSH >2.5 mIU/L may affect embryo implantation rates, and vitamin D deficiency (<30 ng/mL) is associated with an increased risk of miscarriage.
• Uterine Cavity Assessment: Hysteroscopy can rule out endometrial polyps, adhesions, or chronic endometritis, which have a non-negligible incidence in older women and are treatable.

Prognosis is determined by a comprehensive interpretation of these indicators, not a single value. For example, a patient with AMH 0.6 ng/mL but an AFC of 4–5 and FSH 9.2 IU/L may still obtain usable embryos through an individualized ovarian stimulation protocol.

Management Strategies and Goal Differences for Older Patients Across Age Groups

40–42 Years: Strive for Childbirth Using Autologous Oocytes

Patients in this age group still have a reasonable expectation of oocyte yield. The clinical strategy focuses on increasing the euploid embryo rate. Recommendations: ① Use PPOS or luteal phase stimulation protocols to reduce the risk of premature ovulation; ② Mandatory PGT-A screening to avoid implantation failure or early miscarriage from transferring aneuploid embryos; ③ Transfer a single euploid blastocyst per cycle to reduce the risk of multiple pregnancy.

43–44 Years: Prioritize Embryo Accumulation Strategy

In this age group, single-cycle oocyte yield is limited, and the aneuploidy rate is high. The clinical strategy should shift to "multi-cycle embryo accumulation." The specific process is: undergo 2–4 consecutive ovarian stimulation cycles, perform PGT-A on all obtained blastocysts, and proceed with transfer only after accumulating 1–2 euploid embryos. Frozen embryo storage costs in Georgia are lower than in Western Europe, making this strategy feasible.

≥45 Years: Egg Donation Should Be the First-Line Option

When using autologous oocytes, the live birth rate per started cycle is less than 5%, and the miscarriage rate exceeds 50%. From a medical efficiency perspective, egg donation (using a young donor's oocytes) offers a single-transfer live birth rate of 50%–60%, making it a more reliable path to a live birth for women aged ≥45. Georgian law permits egg donation, and waiting times for donor eggs are often shorter than in some other countries. Patients need to understand: the offspring from egg donation will have no genetic link to the recipient, but the recipient carries the pregnancy, and after birth, the child has a legal parent-child relationship with the recipient.

Most Easily Overlooked Clinical Details: Hidden Factors Affecting Success Rates

• Chronic Endometritis: Occurs in approximately 15%–30% of older infertile women. It cannot be detected by routine ultrasound and requires hysteroscopic biopsy plus CD138 immunohistochemistry for diagnosis. Untreated chronic endometritis can reduce implantation rates by 40%.
• Homocysteine Levels: Levels >10 μmol/L are associated with decreased embryo quality and recurrent miscarriage. Supplementation with folic acid, vitamin B6, and B12 can improve this.
• Sperm DNA Fragmentation Index (DFI): Male age also affects embryo developmental potential. When DFI >30%, even if the female partner is 40 years old, the blastocyst formation rate decreases. Georgian fertility centers typically require the male partner to undergo DFI testing concurrently.
• Individualized Luteal Phase Support: Endometrial responsiveness to progesterone may decline in older patients. A combined regimen of vaginal micronized progesterone plus oral dydrogesterone is superior to a single route.

Common Pitfalls: Frequent Misconceptions Among Older Patients

• Myth 1: "IVF success rates in Georgia are much higher than in my home country." Fact: For older patients using autologous oocytes, success rates are determined by the patient's own biological condition, not geographic location. Georgia's advantage lies in its legal allowance for PGT-A and egg donation, not in technology that can reverse oocyte quality.
• Myth 2: "Taking lots of supplements can significantly improve egg quality." Fact: No dietary supplement has been proven to reverse oocyte aging. Coenzyme Q10, DHEA, etc., may modestly improve mitochondrial function in specific populations, but the effect is limited and should not be overstated.
• Myth 3: "PGT-A improves cumulative live birth rates." Fact: PGT-A improves the efficiency of single transfers by selecting euploid embryos, reducing ineffective transfers. However, the cumulative live birth rate depends on the number of euploid embryos available, not the screening itself. For older patients with very low oocyte yield, PGT-A may not be feasible due to an insufficient number of embryos.
• Myth 4: "You don't need domestic tests for IVF in Georgia." Fact: Georgian fertility centers require patients to provide AMH, FSH, infectious disease screening (HIV, Hepatitis B, Hepatitis C, Syphilis), blood type, and karyotype reports from within the last 6 months. Some tests must be completed before departure; otherwise, the stay in Georgia will be prolonged.

Practitioner Observation: Understanding Success Rates in Real Clinical Scenarios

As a reproductive physician with over ten years of clinical experience in assisted reproduction, I observe two extreme mindsets among older patients: one is excessive pessimism, believing that there is no chance at all after age 40; the other is excessive optimism, thinking that "going abroad for IVF guarantees success." The real clinical picture is: for patients aged 40–42, through standardized ovarian stimulation + PGT-A + frozen embryo transfer, approximately one-third can eventually achieve a live birth. However, this process may require 2–4 cycles, take 6–18 months, and cost between 80,000 and 150,000 RMB (at Georgian standards). For patients over 43, a more realistic expectation is needed—the cumulative live birth rate with autologous oocytes drops significantly, and egg donation should be part of the discussion.

Practitioners also observe another easily overlooked fact: in about 20%–25% of older female patients, the male partner is also of advanced age (≥45 years), and elevated sperm DFI in the male can further reduce the blastocyst formation rate. It is recommended that both partners undergo comprehensive testing simultaneously, rather than focusing solely on the female indicators. When treating older couples, Georgian fertility centers routinely require the male partner to provide a semen analysis report from within the last 3 months, including DFI testing.

Specific Process and Timeline: Treatment Pathway for Older Patients Traveling to Georgia

1. Pre-departure Domestic Tests (1–2 months before departure): Complete AMH, FSH, LH, Estradiol, thyroid function, Vitamin D, infectious disease screening, blood type, karyotype; male partner completes semen analysis + DFI. Hysteroscopy is recommended to be done domestically to save time in Georgia.
2. Remote Medical Consultation (2–4 weeks before departure): Send test reports to the Georgian fertility center for the doctor to evaluate and formulate a preliminary stimulation protocol. Also, ensure passport validity covers the entire treatment cycle (recommended validity ≥1 year).
3. First Visit to Georgia (Day 2–3 of menstruation): Upon arrival, complete registration, sign informed consent, undergo vaginal ultrasound to confirm baseline follicle count, and start ovarian stimulation. The stimulation period typically lasts 10–14 days, with follicle development and hormone levels monitored every 2–3 days.
4. Egg Retrieval Surgery (Stimulation Day 12–14): The retrieval procedure takes about 15–20 minutes. Patients can be discharged after 2–4 hours of rest. Luteal phase support medication starts the day after retrieval.
5. Embryo Culture and PGT-A (5–7 days after retrieval): Blastocyst culture is performed. After blastocyst formation, trophectoderm biopsy is done and sent for PGT-A. The testing period is typically 10–14 working days. Patients can return home to wait for results during this time.
6. Frozen Embryo Transfer (After receiving PGT-A report): Select a euploid blastocyst based on the report. Prepare the endometrium (artificial or natural cycle) in the next menstrual cycle. Perform pregnancy test 12–14 days after transfer.

The entire single-cycle process (from stimulation to transfer) usually spans 2–3 months, with the stay in Georgia being 14–18 days. If multiple cycles are needed for embryo accumulation, the overall timeline extends to 6–12 months.

What to Prepare

• Valid passport (validity ≥12 months)
• Reproductive-related test reports from the last 6 months (AMH, FSH, AFC, infectious disease screening, karyotype)
• Domestic hysteroscopy report (if available)
• Male partner's semen analysis report (including DFI)
• Records of previous IVF cycles (medication protocol, oocyte yield, embryo development)
• Health insurance (recommend purchasing travel insurance covering overseas medical care)

What are the Risks

• Medical Risks: Ovarian Hyperstimulation Syndrome (lower incidence in older patients, but still a risk), bleeding or infection from egg retrieval surgery, no euploid embryos available for transfer, miscarriage after transfer (miscarriage rate for advanced maternal age is approximately 30%–50%).
• Non-Medical Risks: Communication errors in跨国医疗, misunderstanding of legal documents, cost fluctuations due to exchange rate changes, risk of thrombosis during flights (recommend wearing compression stockings and moving appropriately during long flights).

Risk Reminder

Before undergoing IVF treatment, older women should fully understand the objective law that the success rate with autologous oocytes declines rapidly with increasing age. Georgia, as a destination for assisted reproduction, offers certain advantages in its legal environment and technical support, but it cannot alter the patient's own biological foundation. It is recommended to complete a comprehensive reproductive evaluation before starting treatment and to reach a clear consensus with the reproductive physician on key issues such as "the maximum number of stimulation cycles acceptable," "acceptance of egg donation," and "embryo disposition plan." Do not invest resources beyond your financial and psychological capacity due to excessive optimism about success rates.